MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
On December 13, 2018, MYOS RENS Technology Inc. (the “Company”) held its 2018 annual meeting of stockholders (the “Meeting”). At the Meeting, stockholders (i) elected three directors to serve as Class I directors on the Company’s board of directors (“Board”) until the 2021 annual meeting of stockholders or until their successors are elected and qualified and (ii) ratified the selection by the Board of WithumSmith+Brown, PC (“Withum”) to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2018.
Set forth below are the final voting results for each of the proposals:
Proposal No. 1 – Election of directors
Dr. Robert J. Hariri, Ren Ren and Eric Zaltas were elected to serve as Class I directors. The voting results were as follows:
| Name | For | Withheld | Broker Non-Vote |
| Dr. Robert J. Hariri | 3,352,842 | 37,010 | 2,958,745 |
| Ren Ren | 3,123,185 | 265,492 | 2,959,920 |
| Eric Zaltas | 3,353,125 | 43,875 | 2,951,597 |
Proposal No. 2 – Ratification of independent registered public accounting firm
The stockholders ratified the selection of Withum to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2018. The voting results were as follows:
| For | Against | Abstentions |
| 6,317,985 | 30,382 |
About MYOS RENS TECHNOLOGY INC. (NASDAQ:MYOS)
MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.